@entity8 ( @entity8 ) remains one of the most common causes of the @entity1985 ( @entity1985 ) in adults. Although the natural history is extremely variable, approximately two thirds of the @entity1 will have persistent high-grade @entity644 and/or develop @entity177 over a decade of observation. On the other hand, the remaining third of @entity1 will remit spontaneously and potentially toxic therapy should be avoided in this group. Our capacity to predict which @entity1 will progress at an early stage of the disease has improved substantially in the past 10 years. We present the data from studies of @entity205 (CSA) and @entity618 ( @entity2098 ) treatment of @entity8 with their level of evidence in support of efficacy. In addition, based on data related to predicting prognosis, we assign a risk for progression category to the trial @entity1 at entry into these studies. The data are presented in this format so the reader will be able to better discern the risk benefit of treatment within each category and the rationale for our subsequent grade of recommendation for the use of these agents in @entity8 . CSA has been shown in randomized controlled trials in both the medium and high risk of progression categories of @entity8 @entity1 to improve @entity644 and preserve renal function at least in the short term in up to two thirds of @entity1 . Other studies suggest prolonged therapy beyond 6 months to 1 year may reduce the high relapse rate after @entity870 treatment supporting more long-term, continuous, or combination therapy in @entity8 treatment. The data in favor of @entity2098 treatment of this disease is much weaker and are derived from pilot studies. Only one report applied @entity2098 specifically to @entity8 @entity1 . In these medium to high risk of progression @entity1 , approximately one-half had a 50% reduction in their baseline @entity644 without a significant alteration in their serum @entity1011 level. @entity2098 's role as a single agent or as adjunctive therapy in the treatment of @entity8 needs more rigorous evaluation.

XXXX and @entity205 therapy in @entity8 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity644 :: ('MESH:D011507', 'Disease') :: ['proteinuria'] @entity8 :: ('MESH:D007674', 'Disease') :: ['IMN', 'Idiopathic membranous nephropathy'] @entity870 :: ('CHEBI:55379', 'Chemical') :: ['CSA'] @entity177 :: ('MESH:D051437', 'Disease') :: ['renal failure'] @entity205 :: ('MESH:D016572', 'Chemical') :: ['cyclosporine'] @entity2098 :: ('CHEBI:8764', 'Chemical') :: ['MMF'] @entity618 :: ('MESH:C063008', 'Chemical') :: ['mycophenolate mofetil'] @entity1011 :: ('MESH:D003404', 'Chemical') :: ['creatinine'] @entity1985 :: ('MESH:D009404', 'Disease') :: ['NS', 'nephrotic syndrome']
@entity618 :: (MESH:C063008,Chemical) :: ['Mycophenolate mofetil']
